Saltar al contenido
Merck

Influence of triiodothyronine on the contractile effect of D-nor-pseudoephedrine.

Proceedings of the Western Pharmacology Society (2010-01-01)
Carlos Castillo-Henkel, Jorge López-Canales, María del Carmen Castillo-Hernández, Juan Asbun-Bojalil, Raul Morín-Zaragoza, Daniel Rodríguez-Choreño
RESUMEN

Here we contrast the vascular smooth muscle contractility produced by D-nor-pseudoephedrine, alone or combined with triiodothyronine, on the aorta and coronary vasculature of the rat. At high concentrations (greater than those found in normal therapeutic dosing) D-nor-pseudoephedrine contracted the aorta. In contrast, it produced vasodilation on pre-contracted aorta independently of the vasoconstrictor employed or the presence of vascular endothelium. D-nor-pseudoephedrine increased coronary perfusion pressure, but the effect was smaller than the vasoconstriction produced by phenylephrine (a full alpha 1 adrenergic agonist), and was blocked by the pre-treatment with triiodothyronine. These results suggest cardiovascular risks in the use of D-nor-pseudoephedrine for weight loss.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
(+)-Norpseudoephedrine hydrochloride solution, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
(1S,2R)-(+)-Norephedrine, 98%
Supelco
(±)-Phenylpropanolamine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
DL-Norephedrine hydrochloride, ≥99%
Sigma-Aldrich
Cathine hydrochloride